8-K: ImmunityBio Soars with 700% Revenue Growth, Global ANKTIVA Approvals

ImmunityBio announced a 700% year-over-year revenue increase for ANKTIVA, expanded global regulatory approvals, and its first lung cancer authorization, signaling strong commercial momentum.

Summary

• Full-year 2025 ANKTIVA net product revenue reached $113 million, representing an approximately 700% increase year-over-year.
• ANKTIVA unit sales volume increased by 750% in 2025 compared to 2024.
• Q4 2025 ANKTIVA net product revenue was $38.3 million, a 20% increase quarter-over-quarter and 431% year-over-year.
• ANKTIVA in combination with BCG for BCG-unresponsive NMIBC CIS is now authorized across four major regulatory jurisdictions: United States, United Kingdom, European Union, and Saudi Arabia, encompassing 33 countries.
• The Saudi Food and Drug Authority (SFDA) granted the first approval for ANKTIVA in combination with checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC) in January 2026, with commercial launch planned within 60 days.
• Long-term patent protection for ANKTIVA combinations with checkpoint inhibitors extends beyond 2035.
• Strategic distribution partnerships were formed with Accord Healthcare in the European Union (30 countries) and BioPharma & Cigalah in Saudi Arabia and the broader Middle East North Africa (MENA) region.
• Cash, cash equivalents, and marketable securities stood at $242.8 million as of December 31, 2025.
• Net loss attributable to ImmunityBio common stockholders for the full year 2025 was $351.4 million, an improvement from $413.6 million in 2024.
• Net loss attributable to ImmunityBio common stockholders for Q4 2025 was $61.9 million, compared to $59.2 million in Q4 2024.
• Research and development (R&D) expense increased to $218.6 million for the full year 2025 (from $190.2 million in 2024) and $63.9 million for Q4 2025 (from $35.2 million in Q4 2024), partly due to a $14.0 million one-time fixed asset write-off.
• Selling, general and administrative (SG&A) expense decreased to $150.0 million for the full year 2025 (from $168.8 million in 2024) and $38.7 million for Q4 2025 (from $41.7 million in Q4 2024).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, driven by exceptional revenue growth, significant global market expansion, and a pivotal first approval for ANKTIVA in lung cancer, despite an increase in Q4 net loss.

Positives

• Exceptional 700% year-over-year growth in ANKTIVA net product revenue to $113 million for full-year 2025.
• Significant 750% increase in ANKTIVA unit sales volume in 2025 compared to 2024.
• Rapid global regulatory expansion, with ANKTIVA now authorized in 33 countries across four major jurisdictions (US, UK, EU, Saudi Arabia) within two years of initial FDA approval.
• First-ever approval for ANKTIVA in lung cancer (metastatic NSCLC) by the Saudi FDA, validating its role beyond bladder cancer and opening a new therapeutic area.
• Strong patent protection for ANKTIVA combinations with checkpoint inhibitors extending beyond 2035, ensuring long-term commercial exclusivity.
• Strategic commercial partnerships established in Europe (Accord Healthcare) and the Middle East (BioPharma & Cigalah) to support global launches and market penetration.
• Reduction in full-year net loss attributable to common stockholders from $413.6 million in 2024 to $351.4 million in 2025.
• Increased cash and marketable securities position to $242.8 million as of December 31, 2025, from $149.8 million in 2024.

Negatives

• Net loss attributable to ImmunityBio common stockholders increased to $61.9 million in Q4 2025 from $59.2 million in Q4 2024.
• Research and development expense increased significantly by $28.7 million in Q4 2025 and $28.4 million for the full year 2025, partly due to a $14.0 million one-time fixed asset write-off.

Risks

• Risks and uncertainties regarding commercial launch execution, success, and timing.
• Risks and uncertainties regarding the FDA regulatory submissions, filings, and review processes and the timing thereof, as well as other global regulatory agencies.
• The risk that the FDA may require additional data, analyses, or clinical studies, including randomized or controlled trials, or may not agree with the Company’s interpretations of clinical results.
• The risk that prior or future regulatory feedback, meeting discussions, or communications may not result in a path to approval on the timelines anticipated or at all.
• The risk that real-world experience may differ from results observed in clinical trials.
• ImmunityBio’s ability to submit the regulatory submissions referenced herein on the anticipated timeline or at all.
• Foreign currency fluctuations, geopolitical or economic conditions in the region, and other risks related to international commercialization of an innovative biologic product.
• The ability of ImmunityBio to fund its ongoing and anticipated clinical trials.
• Whether clinical trials will result in registrational pathways.
• Whether clinical trial data will be accepted by regulatory agencies.
• Risks and uncertainties regarding changes in personnel at the FDA and limited resources at the FDA and potential delays associated therewith.
• The ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions.
• Potential delays in product availability and regulatory approvals.
• ImmunityBio’s ability to retain and hire key personnel.
• ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates.
• Potential product shortages or manufacturing disruptions that may impact the availability and timing of product.
• Risks and uncertainties associated with third-party collaborations and agreements.
• ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products.
• ImmunityBio’s ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies.

Future Outlook

ImmunityBio plans to pursue accelerated approvals for ANKTIVA in NSCLC in multiple additional jurisdictions (Ex-USA) in 2026 and engage with the U.S. FDA for a regulatory pathway. The company is also pursuing further label expansion across multiple tumor types and for the treatment of chemotherapy-induced lymphopenia, supported by ongoing clinical trial programs. A Biologics License Application (BLA) filing for the BCG-nave bladder cancer randomized trial is targeted by Q4 2026.

Management Comments

• "In under two years from initial FDA approval, ImmunityBio has built a global commercial footprint spanning 33 countries across four regulatory jurisdictions, with $113 million in full-year net product revenue representing 700% year-over-year growth." Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer.
• "The SFDA’s accelerated approval of ANKTIVA in combination with checkpoint inhibitors for metastatic NSCLC marks a defining moment for the Company, the first authorization of ANKTIVA beyond bladder cancer and the first validation of its role as a lymphocyte-stimulating agent in solid tumors." Dr. Patrick Soon-Shiong.
• "Our 2025 financial results reflect the growing clinical adoption of ANKTIVA as a foundational backbone of immunotherapy for bladder cancer." Richard Adcock, President and CEO.
• "As we advance toward initial international commercial activities, we remain focused on disciplined execution: completing enrollment in our BCG-nave randomized trial with a BLA filing targeted by Q4 2026, expanding the ANKTIVA label into lung cancer and lymphopenia, and converting our 700% revenue growth trajectory into durable, long-term value for shareholders." Richard Adcock.

Industry Context

StockSavvy.ai notes that ImmunityBio's rapid global expansion and the first approval of ANKTIVA for lung cancer position it as a significant player in the competitive immunotherapy landscape. The focus on combination therapies and a broad pipeline across multiple tumor types aligns with the industry trend towards multi-modal approaches to cancer treatment, particularly leveraging IL-15 superagonists and checkpoint inhibitors. The company's strategy to establish a "Cancer BioShield Platform" with ANKTIVA as a backbone reflects a comprehensive approach to immune activation, potentially differentiating it from competitors focusing on single-target therapies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard comparison.

Related Party Transactions

• Change in fair value of a related-party convertible note contributed to the increase in Q4 net loss.
• Interest expense related party was $(14,843) thousand in Q4 2025 and $(60,886) thousand for full-year 2025.
• Research and development related parties was $3,049 thousand in Q4 2025 and $10,684 thousand for full-year 2025.
• Selling, general and administrative related parties was $896 thousand in Q4 2025 and $2,823 thousand for full-year 2025.

Stakeholder Impact

• Shareholders: Significant revenue growth and global expansion could lead to increased shareholder value. Reduced full-year net loss is positive, but increased Q4 net loss and R&D expenses warrant attention. Potential for long-term value creation through pipeline advancement and patent protection.
• Patients: Expanded access to ANKTIVA in 33 countries for bladder cancer and new approval for lung cancer in Saudi Arabia offers new treatment options. Ongoing clinical trials aim to address other cancers and conditions like lymphopenia and sepsis.
• Employees: Growing sales and marketing activities led to higher headcount costs, suggesting job growth in commercial roles.
• Regulatory Authorities: The company is actively engaging with regulatory bodies (FDA, MHRA, SFDA, European Commission) for approvals and label expansions, demonstrating compliance and commitment to bringing therapies to market.

Next Steps

• Commercial launch of ANKTIVA for metastatic NSCLC in Saudi Arabia within 60 days of January 2026 approval.
• Planned submissions to multiple additional regulatory authorities (Ex-USA) for accelerated approval for NSCLC in 2026.
• Discussions planned with the U.S. FDA in 2026 regarding an accelerated approval pathway for NSCLC.
• Pursuing further label expansion across multiple tumor types and for the treatment of chemotherapy-induced lymphopenia.
• Completing enrollment in the BCG-nave randomized trial (QUILT-2.005) with a BLA filing targeted by Q4 2026.
• Planned submission to SFDA and U.S. FDA meeting scheduled for March 2026 regarding Recombinant BCG regulatory.
• Advancing enrollment in ongoing and planned key randomized clinical trials across multiple therapeutic areas, including NMIBC, NSCLC, Pancreatic Cancer, HCC, Colorectal Cancer, Triple Negative Breast Cancer, Glioblastoma, Non-Hodgkin Lymphoma, Sepsis, Radiation-Induced Lymphopenia, and Multiple Myeloma.

Key Dates

Recommendation

The filing demonstrates exceptional commercial traction for ANKTIVA with 700% year-over-year revenue growth and a 750% increase in unit sales, significantly exceeding expectations for a newly approved product. The rapid global regulatory expansion into 33 countries and the pivotal first approval for lung cancer in Saudi Arabia validate ANKTIVA's broad potential and open substantial new markets. While Q4 net loss increased, the full-year net loss decreased, and the robust revenue growth, strong cash position, and extensive pipeline with long-term patent protection indicate a strong growth trajectory and significant future value creation potential for investors. The strategic partnerships and established global infrastructure further de-risk commercial execution.

Keywords

ImmunityBio, IBRX, ANKTIVA, immunotherapy, cancer treatment, bladder cancer, lung cancer, NMIBC, NSCLC, oncology, biotechnology, pharmaceutical, FDA approval, regulatory approval, commercialization, revenue growth, clinical trials, IL-15 superagonist, checkpoint inhibitors, CAR-NK, patent protection